DiaMedica Therapeutics DMAC Stock
DiaMedica Therapeutics Price Chart
DiaMedica Therapeutics DMAC Financial and Trading Overview
| DiaMedica Therapeutics stock price | 5.65 USD |
| Previous Close | 5.99 USD |
| Open | 5.91 USD |
| Bid | 4.3 USD x 200 |
| Ask | 7.37 USD x 200 |
| Day's Range | 5.75 - 6.04 USD |
| 52 Week Range | 3.48 - 10.42 USD |
| Volume | 178.33K USD |
| Avg. Volume | 191.7K USD |
| Market Cap | 314.68M USD |
| Beta (5Y Monthly) | 0.988 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.71 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 15.5 USD |
DMAC Valuation Measures
| Enterprise Value | 271.64M USD |
| Trailing P/E | N/A |
| Forward P/E | -6.636364 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 6.6590652 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -7.403 |
Trading Information
DiaMedica Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.988 |
| 52-Week Change | 43.64% |
| S&P500 52-Week Change | 27.69% |
| 52 Week High | 10.42 USD |
| 52 Week Low | 3.48 USD |
| 50-Day Moving Average | 6.37 USD |
| 200-Day Moving Average | 7.18 USD |
DMAC Share Statistics
| Avg. Volume (3 month) | 191.7K USD |
| Avg. Daily Volume (10-Days) | 157.12K USD |
| Shares Outstanding | 53.88M |
| Float | 28.6M |
| Short Ratio | 30.53 |
| % Held by Insiders | 27.73% |
| % Held by Institutions | 37.77% |
| Shares Short | 4.84M |
| Short % of Float | 13.40% |
| Short % of Shares Outstanding | 8.98% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:20 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2025 |
| Most Recent Quarter (mrq) | March 31, 2026 |
| Next Fiscal Year End | December 31, 2026 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -49.96% |
| Return on Equity (ttm) | -86.46% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -36692000 USD |
| Net Income Avi to Common (ttm) | -35101000 USD |
| Diluted EPS (ttm) | -0.71 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 51.33M USD |
| Total Cash Per Share (mrq) | 0.95 USD |
| Total Debt (mrq) | 212K USD |
| Total Debt/Equity (mrq) | 0.45 USD |
| Current Ratio (mrq) | 9.11 |
| Book Value Per Share (mrq) | 0.877 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -30995000 USD |
| Levered Free Cash Flow (ttm) | -18008376 USD |
Profile of DiaMedica Therapeutics
| Country | United States |
| State | MN |
| City | Minneapolis |
| Address | 301 Carlson Parkway |
| ZIP | 55305 |
| Phone | 763 496 5454 |
| Website | https://www.diamedica.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 35 |
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Q&A For DiaMedica Therapeutics Stock
What is a current DMAC stock price?
DiaMedica Therapeutics DMAC stock price today per share is 5.65 USD.
How to purchase DiaMedica Therapeutics stock?
You can buy DMAC shares on the Tech Market Small exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for DiaMedica Therapeutics?
The stock symbol or ticker of DiaMedica Therapeutics is DMAC.
Which industry does the DiaMedica Therapeutics company belong to?
The DiaMedica Therapeutics industry is Biotechnology.
How many shares does DiaMedica Therapeutics have in circulation?
The max supply of DiaMedica Therapeutics shares is 53.88M.
What is DiaMedica Therapeutics Price to Earnings Ratio (PE Ratio)?
DiaMedica Therapeutics PE Ratio is now.
What was DiaMedica Therapeutics earnings per share over the trailing 12 months (TTM)?
DiaMedica Therapeutics EPS is -0.71 USD over the trailing 12 months.
Which sector does the DiaMedica Therapeutics company belong to?
The DiaMedica Therapeutics sector is Healthcare.
DiaMedica Therapeutics DMAC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| US Tech Composite IXIC | 26853.98 USD — |
-0.89
|
8.32B USD — | 26769.16 USD — | 27130.88 USD — | — - | 8.32B USD — |
| US Tech Capital Market Composite RCMP | 148.96 USD — |
-1.84
|
— — | 148.23 USD — | 151.02 USD — | — - | — — |
| US Tech Health Care IXHC | 1133.51 USD — |
+1.54
|
— — | 1113.35 USD — | 1133.95 USD — | — - | — — |
- {{ link.label }} {{link}}